الفهرس 
ACKNOWLEDGMENTOnly 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
Assessment of a patient’s disease severity is an essential component of formulating therapeutic strategies.However, disorders of the skin are often not subject to strict classification criteria. Methods of evaluating the severity of skin diseases are often crude, subjective and not reproducible, which creates discrepancy in results and inter-individual variations. Scoring systems quantify and collate relevant data in a compact form that can be used to guide clinical management. A number of grading systems have developed to standardize end points in clinical trials, facilitate disease management and follow therapeutic response (Grekin and Ellis, 2009). The aim of the present study was to conduct a literature review of scoring systems in some dermatological diseases and to assess the effect of two treatment modalities (systemic steroid alone and systemic steroid with Azathioprine) in the treatment of pemphigus vulgaris by using the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). Dermatological diseases that reviewed for scoring systems in the present study were, Atopic dermatitis (SCORAD, EASI); Vitiligo (VIDA, VASI and VETI); Cutaneous lupus erythematosus (CLASI); Alopecia areata (SALT score);Hyperpigmentation (Visual hyperpigmentation scale and Melasma area and severity index); Hirsutism (Ferriman and Gallwey score); Psoriasis (PASI and PGA); Nail psoriasis (NAPSI); Acne vulgaris (Acne lesion count, GAGS, Cook’s method, Leeds technique and Michaelsson score); Rosacea (Plewig and Kligman Score); Toxic epidermal necrolysis (SCORTEN); Scleroderma (MRSS) ; Dermatomyositis (DSSI); Urticaria (UAS); Onychomycosis (OSI); Pemphigus vulgaris (ABSIS and PAAS).The practical part of the present study was conducted on 10 patients with pemphigus vulgaris. Patients were classified into two groups, group І (5 patients) were on systemic corticosteroid and group ІІ (5 patients) were on systemiccorticosteroid and azathioprine as an adjuvant therapy. The effect of treatment was assessed by using the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). This study demonstrated that treatment with systemic corticosteroid alone or in combination with adjuvant azathioprine can control pemphigus vulgaris with no significant difference between the two lines of treatment. There is a pressing need for evidence to guide the selection of treatment modalities, drug dosages, routes of administration, and weaning programs. Therefore, large multicenter randomized clinical trials are recommended to establish best treatment of pemphigus. Larger sample sizes and randomized blind design are suggested for future studies.